Another study demonstrated that combining entinostat with anti-PD-1, anti-CTLA-4, or both significantly improved tumor-free survival in HER2/neu transgenic breast cancer and Panc02 metastatic pancreatic cancer mouse models. Here, ERBB2 is linked to neoplasm.